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PainConvolutamydine A has been shown to develop a signiﬁcant antinociceptive effect. Here we demonstrated that
new analogues (5-iodo-3-(2-oxopropyl)-3-hydroxy-2-oxindole (5-Iisa), 5-ﬂuoro-3-(2-oxopropyl)-3-hydroxy-
2-oxindole (5-Fisa), 5-chloro-3-(2-oxopropyl)-3-hydroxy-2-oxindole (5-Clisa) and 5-methyl-3-(2-oxopropyl)-
3-hydroxy-2-oxindole (5-Meisa)), at 0.1–10mg/kg doses, have signiﬁcant peripheral and central antinociceptive
effects in thermal and chemical models of nociception. Oral administered analogues demonstrated more pro-
nounced antinociceptive effects than that obtained with the classical opioid drug morphine (5 mg/kg) in the
ﬁrst and second phases of formalin-induced licking. In the tail ﬂick model, 5-Clisa and 5-Meisa antinociceptive
effect was almost twice as that observed with the same dose of morphine. The concomitant administration of di-
verse antagonists and the analogues indicates that 5-Iisa effects involve the activation of opioid pathway. On the
other hand, 5-Fisa and 5-Clisa have the participation of opioid, nitrergic, cholinergic adrenergic and serotoniner-
gic pathways and 5-Meisa has the involvement of opioid, serotoninergic and cholinergic pathways. In conclusion,
our results suggest that the new four analogues from Convolutamydine A have signiﬁcant antinociceptive effects
in thermal and chemical induced nociception and could be used in development of new drugs to be used in pain
treatment with reduced side effects.
© 2015 Elsevier Inc. All rights reserved.1. Introduction
Pain is a hallmark of inﬂammation, and the therapeutic approaches
to pain relief are based upon non-steroidal anti-inﬂammatory drugs or
opiates. The improper use of either class of drugs gives rise to several
unwanted effects such as ulcers, vomiting, tolerance, and dependence
(Nakagawa and Kaneko, 2010; Zhao et al., 2011). The inevitable side ef-
fects associated with the use of these classes of drugs have led to the
search for and synthesis of new efﬁcient analgesics presenting little or
no side effects in pain control.
Convolutamydine A is a member of a family of oxindole alkaloids
isolated from the Floridian marine bryozoan Amathia convoluta. This
compound is interesting, as it has been described in the literature as
having signiﬁcant pharmacological activity. Several analogues have
been synthesised fromConvolutamydine A that demonstrate a diversity
of effects (Kamano et al., 1995; Garden et al., 1997; Luppi et al., 2006;
Cravotto et al., 2006). Our group described anti-inﬂammatory and/ors).antinociceptive effects for a diversity of analogues (Matheus et al,
2007; Figueiredo et al, 2013; Fernandes et al., 2014).
In this study we examine the antinociceptive effects of four synthe-
sised 3-(2-oxopropyl)-3-hydroxy-2-oxindoles using thermal and in-
ﬂammatory pain models in mice. We further evaluate the possible
mechanisms of action of these substances with the hope of suggesting
them as potential antinociceptive therapeutic agents.
2. Materials and methods
2.1. Animals
All experiments were performed with male Swiss Webster mice
(20–25 g) donated by Instituto Vital Brazil (Niterói, Brazil). The animals
weremaintained in a roomwith controlled temperature (22± 2 °C) on
a 12-h light/dark cycle, with free access to food and water. All efforts
were made to minimise animal suffering, to reduce the number of ani-
mals used. All animal experimental protocols are in compliance with
the National Institutes of Health Guide for Care and Use of Laboratory
Animals (Publication No. 85-23, revised 1985), the UK Animals (Scien-
tiﬁc Procedures) Act, 1986 and associated guidelines, the National Insti-
tutes of Health Guide for the Care and Use of Laboratory Animals (NIH
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also in accordance with the principles and guidelines adopted by the
Brazilian College of Animal Experimentation (COBEA). Research proto-
cols were approved by the Ethical Committee for Animal Research
(Biomedical Science Institute/UFRJ) and received the approval number
DFBCICB015-04/16.
2.2. General
Acetylsalicylic acid (ASA), dexamethasone, atropine sulphate
monohydrate, capsaicin, L-glutamic acid (glutamate), L-nitro arginine
methyl ester (L-NAME), and carrageenan were purchased from Sigma
(St. Louis, MO, USA), and formalin was purchased from Merck, Inc.
Morphine sulphate and naloxone hydrochloride were kindly provided
by Cristália (São Paulo, Brazil). All drugs were dissolved in phosphate
buffer saline (PBS) just before use. Capsaicin was dissolved in 80% (v/v)
ethanol plus 20% PBS. ASA (200 mg/kg, po) and dexamethasone
(5 mg/kg, ip) were used as reference drugs. The negative control group
was treated with the vehicle.
2.3. Synthesis of substances
Isatins were suspended in acetone, and drops of diethylamine were
added at room temperature, leading to 5-iodo-3-(2-oxopropyl)-3-hy-
droxy-2-oxindole (5-Iisa), 5-ﬂuoro-3-(2-oxopropyl)-3-hydroxy-2-
oxindole (5-Fisa), 5-chloro-3-(2-oxopropyl)-3-hydroxy-2-oxindole
(5-Clisa) and 5-methyl-3-(2-oxopropyl)-3-hydroxy-2-oxindole (5-
Meisa) (Fig. 1). The structures of the ﬁnal compounds were determined
by 1H-NMR and 13C-NMR, as described by Garden et al. (1997).
2.4. Administration of substances
5-Iisa, 5-Fisa, 5-Clisa and5-Meisawere dissolved indimethylsulphoxide
(DMSO) to prepare stock solutions at 100 mg/ml. All substances were
administered by oral gavage at doses of 0.1 to 10 mg/kg in a ﬁnal
volume of 0.1ml of Tween 80 per animal. The control groupwas treated
with vehicle (Tween 80/DMSO). In all experiments, the ﬁnal concentra-
tion of DMSO or Tween 80 had no effect per se.
2.5. Acute toxicity
Acute toxicity was determined according to the experimental model
described by Lorke (1983). A single oral dose (150 mg/kg) of a sub-
stance was administered to a group of ten mice (ﬁve males and ﬁve fe-
males). Behavioural parameters, including convulsion, hyperactivity,
sedation, grooming, loss of righting reﬂex, increased or decreased respi-
ration, and food and water intake, were observed over a period of
5 days. After this period, the animals were sacriﬁced by cervical disloca-
tion, their stomachs were removed, an incision was made along the
greater curvature, and the number of ulcers (single ormultiple erosions,
ulcers or perforations) and degree of hyperaemia were counted.Fig. 1. General structure of oxopropyl-oxindoles.2.6. Formalin-induced licking model
Theprocedurewas similar to themethod described byHunskaar and
Hole (1987) and with some modiﬁcations performed by Gomes et al.
(2007). Animals received 20 μl of formalin (2.5% v/v) into the dorsal sur-
face of the left hind paw. The time of licking the formalin-injected paw
was immediately recorded during two phases: ﬁrst phase (neurogenic
pain response) between themoment of injection and 5min and second
phase (inﬂammatory pain response) between 15 and 30 min post-
injection. The animals were pretreated with oral doses of each com-
pound (0.1, 1 or 10 mg/kg), morphine (5 mg/kg), ASA (200 mg/kg), or
vehicle (PBS) 60 min before the administration of formalin.2.7. Glutamate- or capsaicin-induced nociception
The procedure used for glutamate-induced nociception was de-
scribed by Beirith et al. (2002) and adopted by Pinheiro et al. (2013),
and for capsaicin-induced nociception the protocol described by
Sakurada et al. (1998) was adopted by Pinheiro et al. (2013). Brieﬂy,
an intraplantar injection of glutamate (10 μl, 3.7 ng/paw) or capsaicin
(20 μl; 1.6 μg/paw) was administered to the right hind paw. The animal
was immediately placed in an individual box, and the time that the an-
imal sustained licking or biting of the glutamate- or capsaicin-injected
paw was recorded for 15 or 5 min, respectively. Mice were orally
pretreated 60min before the intraplantar injection of glutamate or cap-
saicin with each substance (0.1, 1 or 10 mg/kg) or vehicle.2.8. Tail ﬂick
This test was performed according to Bem-Bassat et al. (1959) and
adapted by Pinheiro et al. (2010). Brieﬂy, micewere placed in a contain-
er tube, and one third of the tail was immersed in a water bath set to
50 ± 1 °C. The reaction time necessary for the animal to withdraw the
tail was registered at several intervals of 20min after the administration
of a substance (0.1 to 10 mg/kg), morphine (5 mg/kg) or vehicle. Base-
line was designated as the average of the reaction times obtained at 40
and 20min before the administration of the substance, morphine or ve-
hicle and deﬁned as the normal reaction of the animal to thermal stim-
ulus. If the animal did not withdraw their tail from the hot water for a
period of time greater than three times the baseline (cut-off), their tail
was manually removed to avoid any possible damage. Antinociception
was quantiﬁed as an increase in baseline (IB) (%) calculated by the
formula: IB = ((reaction time × 100) / baseline)− 100 or area under
the curve (AUC) calculated by the formula based on the trapezoid rule
of responses from 20 min after drug administration until the end of
the experiment (Matthews et al., 1990): AUC = 20 × IB [(min 20) /
2 + (min 20 + min 40) / 2 + (min 40 + min 60) / 2…+ (min 120) /
2]. The baselines values varied between 4 and 7 s.2.9. Evaluation of the possible mechanism(s) of action of substances in the
tail ﬂick test
To assess the possible participation of the opioid, cholinergic, norad-
renergic, nitrergic, serotoninergic and cannabinoid systems in the
antinociceptive effect of the substances, micewere pretreated with nal-
oxone (opioid antagonist, 5mg/kg, ip),mecamylamine (nicotinic antag-
onist, 2 mg/kg, ip), atropine (muscarinic antagonist, 1 mg/kg, ip),
ondansetron (5-HT3 serotoninergic antagonist, 0.5 mg/kg, ip), yohim-
bine (alpha-2 adrenergic antagonist, 2 mg/kg, ip), or L-nitro arginine
methyl ester (L-NAME, inhibitor of nitric oxide synthase, 3 mg/kg, ip)
15 min before treatment with a compound (10 mg/kg, po). Dose re-
sponse curves for each antagonist were previously constructed and
the dose that reduced the response to the agonist by 50% was chosen
for these assays (Pinheiro et al., 2010; Figueiredo et al, 2013).
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All experimental groups contained 6–10 mice. The results are pre-
sented as the mean ± SD. The signiﬁcance of the difference between
the mean values was evaluated with GraphPad Prism™ (version 5.00,
GraphPad Software Inc., San Diego, CA, USA) by analysis of variance
(ANOVA) followed by Bonferroni's tests. P values less than 0.05 were
considered to indicate signiﬁcant differences.3. Results
In the present study the antinociceptive efﬁcacy of four 3-(2-
oxopropyl)-3-hydroxy-2-oxindoles was evaluated in several models of
antinociception. Intraplantar injection of formalin produced a signiﬁ-
cant licking response in the formalin-injected paw of 46 ± 2.3 s
(1st phase) and 145 ± 15 s (2nd phase). All three doses (0.1, 1 or
10mg/kg) of each substance (5-Iisa, 5-Fisa, 5-Clisa and 5-Meisa) signif-
icantly reduced both the 1st and 2nd phases of the formalin-licking re-
sponse. It is also interesting to note that all substances had an effect in
the 1st phase, and higher doses of 5-Iisa and 5-Fisa had a signiﬁcant in-
hibitory effect (in 2nd phase) compared with the ASA-treated group
(Fig. 2).
To investigate the antinociceptive effects of 5-Iisa, 5-Fisa, 5-Clisa and
5-Meisa we examined their effects on the tail ﬂick model of thermal
nociception. The results of Fig. 3 show that all compounds tested dem-
onstrated an antinociceptive effect with differences occurring between
each one. Effects higher than a 50% increase in baseline were observed
with 1 and 10 mg/kg doses. For both doses the results varied between
a 50% and 150% increase in baseline. The effects of 5-Iisa, 5-Fisa and
5-Clisa seem to reach a plateau at 80 or 100 min post-administration.
When the time course curve was converted to an area under the
curve (AUC) graph it was observed that 5-Clisa and 5-Meisa at
10 mg/kg had an effect signiﬁcantly higher than that of morphine
(Fig. 4).Fig. 2. Effects of 5-Iisa, 5-Fisa, 5-Clisa and 5-Meisa on formalin-induced licking behaviour.
Mice were pretreated with one of the substances, acetylsalicylic acid (ASA, 200 mg/kg),
morphine (5 mg/kg) or vehicle. The results are presented as the mean ± SD (n = 6–10)
of the time that the animal spent licking the formalin-injected paw. Statistical signiﬁcance
was calculated by ANOVA followed by Bonferroni's test. *P b 0.05 compared to vehicle-
treated mice; #P b 0.05 compared to the morphine-treated group; P b 0.05 compared to
the ASA-treated group.To further evaluate their antinociceptive activity the substances
were tested in capsaicin- (Fig. 5A) and glutamate- (Fig. 5B) induced
licking behaviour. Although all substances inhibited the licking re-
sponse to both agonists, this inhibitory effect was more pronounced
with 5-Clisa and 5-Meisa pretreatment. Moreover, the effects of both
substances against the glutamate-induced response were stronger
than those obtained with 5-Iisa or 5-Fisa.
As 5-Iisa, 5-Fisa, 5-Clisa and 5-Meisa demonstrated signiﬁcant pe-
ripheral and spinal antinociceptive effects, we further tried to evaluate
the mechanism of action of the substances in the tail ﬂick model. For
this purpose we assessed the participation of endogenous systems
(the opioid, cholinergic, adrenergic, nitrergic and serotoninergic
systems) in the antinociceptive effects of the substances. Signiﬁcant dif-
ferences occurred between the inhibitory effects against each sub-
stance. Whereas naloxone (opioid receptor antagonist, 1 mg/kg, po)
only reverted the antinociceptive effect of 5-Iisa, the effects of 5-Fisa
and 5-Clisa were reverted by all antagonists used (L-NAME [inhibitor
of the nitric oxide synthase enzymes, 3 mg/kg, po]; mecamylamine
[nicotinic antagonist, 2 mg/kg, ip]; atropine [muscarinic antago-
nist, 1 mg/kg, ip]; ondansetron [5-HT3 serotoninergic antagonist,
0.5 mg/kg, ip]; yohimbine [alpha-2 adrenergic antagonist, 2 mg/kg, ip]).
On the other hand, 5-Meisa's antinociceptive effect was inhibited by
pretreatment of mice with naloxone, atropine or ondansetron (Fig. 6).
We also evaluated the effects of antagonists in the model of
formalin-induced licking response. Atropine did not demonstrate any
signiﬁcant effect versus either substance in either phase (1st or 2nd).
Naloxone was the only antagonist that reverted the inhibitory effect of
all the substances. Although L-NAME, mecamylamine and ondansetron
reverted the 2nd phase of the licking response to all substances, the ef-
fects of these three antagonists in the 1st phase were variable (Fig. 7).
In view of the signiﬁcant results obtained in several models we also
decided to further evaluate a possible toxic effect. Even when a dose of
150 mg/kg was used any kind of behavioural or histological alteration
was observed (data not shown) suggesting that, at the doses used,
these substances do not induce visual signs of toxicity.
4. Discussion
In the present study we investigated the antinociceptive effects of
four 3-(2-oxopropyl)-3-hydroxy-2-oxindoles using inﬂammatory and
thermal pain models in mice.
One interesting ﬁnding of this study was that when administered
orally, all substances caused inhibition of the formalin-induced nocicep-
tive response, even at doses as low as 0.1mg/kg. Moreover, these effects
were observed in both the 1st and 2nd phases. After subcutaneous
injection of formalin an array of stereotyped responses occur that
characterise the model as a useful methodology for studying acute and
tonic pain. The ﬁrst phase (or neurogenic) is due to stimulation of
nociceptors, whereas the second phase (or inﬂammatory) is mediated
by peripheral and spinal cord sensitisation (Hunskaar and Hole, 1987;
Tjølsen et al., 1992). It was also shown that several mediators, such as
amino acids, prostaglandin E2, nitric oxide (NO), substance P (SP), sero-
tonin (5-HT) and histamine are increased at the spinal level (Tjølsen
et al., 1992; Parada et al., 2001). Our results indicate that the four
substances may act through nociceptors (because inhibition of the
ﬁrst phasewas observed) or through altered sensitisation of the periph-
eral or spinal cord. It is also possible that a reduction in some of the in-
ﬂammatory mediators liberated in the paw occurs. The administration
of L-NAME (a NO synthase inhibitor) signiﬁcantly reversed the
antinociceptive effect induced by the oxindoles in the formalin-
induced licking behaviour. These data support the idea that the sub-
stances produce their antinociceptive effects through the involvement
of nitric oxide pathways, as is the case for some anti-inﬂammatory
drugs (Aguirre-Bañuelos and Lozano-Cuenca et al., 2005). Ondansetron
(a 5-HT3 receptor antagonist) also reversed the effects of all oxindoles
suggesting the involvement of the 5-HT3 receptor subtype pathway in
Fig. 3. Effects of 5-Iisa, 5-Fisa, 5-Clisa and 5-Meisa in the tail ﬂickmodel inmice.Micewere pretreatedwith one of the substances,morphine (5mg/kg) or vehicle. The results are presented
as themean± SD (n=6–10) of the increase in baseline. Statistical signiﬁcancewas calculated byANOVA followed by Bonferroni's test. *P b 0.05when comparing treatedmice to vehicle-
treated mice. Where no error bars are shown it is because they are smaller than the symbol.
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other data showing that 5-HT receptor antagonists reduce the second
phase of formalin-induced aversive responses without affecting the
ﬁrst one (Oyama et al., 2002; Bardin et al., 2001).
Putative inﬂammatory mediators such as glutamate and capsaicin
are also able to induce nociceptive pain responses after injection into
the paw (Carstens, 1997; Hong and Abott, 1994). Based on this evi-
dence, we sought to determine whether the four compounds inhibit
the nociceptive response caused by intraplantar injection of glutamate
or capsaicin into the mouse hindpaw. Our data demonstrate that the
compounds produced a signiﬁcant inhibition of the licking responseFig. 4. Effects of 5-Iisa, 5-Fisa, 5-Clisa and 5-Meisa in the tail ﬂickmodel inmice.Micewere
pretreatedwith one of the substances, morphine (5mg/kg) or vehicle. The results are pre-
sented as themean± SD (n=6–10) of the area under the curve (AUC). Statistical signif-
icance was calculated by ANOVA followed by Bonferroni's test. *P b 0.05 when comparing
treated mice to vehicle-treated mice and #P b 0.05 when comparing substance-treated
mice with morphine-treated animals.
Fig. 5. Effects of 5-Iisa, 5-Fisa, 5-Clisa and 5-Meisa on capsaicin (A) and glutamate
(B) induced licking behaviour. Mice were orally pretreatedwith each substance or vehicle
60min before capsaicin or glutamate injection into their paw. The results are presented as
themean± SD (n=6–10) of the time that the animal spent licking the capsaicin- or glu-
tamate-injected paw. Statistical signiﬁcance was calculated by ANOVA followed by
Bonferroni's test. *P b 0.05 when comparing treated mice to vehicle-treated animals.
Fig. 6. Effects of 5-Iisa, 5-Fisa, 5-Clisa and 5-Meisa in the tail ﬂick model. Mice were
pretreated with naloxone (opioid antagonist, 5 mg/kg, ip), mecamylamine (nicotinic
antagonist, 2 mg/kg, ip), atropine (muscarinic antagonist, 1 mg/kg, ip), ondansetron
(5-HT3 serotoninergic antagonist, 0.5 mg/kg, ip), yohimbine (alpha-2 adrenergic antago-
nist, 2 mg/kg, ip) or L-nitro arginine methyl ester (L-NAME, inhibitor of nitric oxide syn-
thase, 3 mg/kg, ip) 15 min before oral administration of substances (10 mg/kg, po) or
vehicle. The results are presented as the mean ± SD (n = 6–10) of the area under the
curve (AUC). Statistical signiﬁcance was calculated by ANOVA followed by Bonferroni's
test. *P b 0.05 when comparing treated mice to vehicle-treated mice and #P b 0.05 when
comparing antagonist-treated groups with substances-treated animals.
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This inhibitory effect seems to be more pronounced in animals whose
paws were injected with glutamate. Thus, the present results indicate
that, at least in part, the antinociceptive action caused by oxindolescould be due to an interaction with the glutamatergic system. Capsaicin
acts through vanilloid receptor type-1 (TRPV-1) expressed on nocicep-
tive ﬁbres and in the dorsal root ganglion of the spinal cord, trigeminal
ganglia and central nervous system (Jancso, 1978; Oyama et al., 2002).
The activation of TRPV1 receptors is alsomediated by the release of neu-
rotransmitters (i.e., glutamate and substance P), an effect that can par-
ticipate in nociceptive processing (Afrah et al., 2001; Medvedeva et al.,
2008). Glutamate is another neurotransmitter involved in nociceptive
transmission, the development and maintenance of a nociceptive re-
sponse through activation of ionotropic or metabotropic receptors,
resulting in nociceptor sensitisation (Aanonsen and Wilcox, 1989;
Budai et al., 1995; Carlton, 2001). An intraplantar injection of glutamate
also induces the release of excitatory amino acids, PGE2, NO and kinins
(Beirith et al., 2002; Sakurada et al., 1998) and promotes the activation
of sensitive ﬁbres that induce the release of several substances in the
dorsal horn, which also can activate the TRPV1 receptor in the spinal
cord (Julius and Basbaum, 2001; Millan, 2002). Our results are in accor-
dance with previous data because the oxindoles reduce the nociceptive
effects evoked by both glutamate and capsaicin. These results indicate
that the antinociceptive effect of our substances involves, at least in
part, the glutamatergic system. In addition to the results obtained in
the capsaicin-induced nociception test, it is possible that they could pro-
duce antinociception by regulating TRPV1 receptors, thus contributing
to the modulation of nociceptive transmission.
To assess whether there would be spinal involvement in the spinal
effect of oxindoles, we evaluated their antinociceptive effects in the
tail ﬂickmodel. All four substances had effects comparable to morphine
with slight differences. The opioid reached its maximal effect at 80 min
post-administration and decayed thereafter, whereas oxindoles
reached their maximal effect sooner (i.e., 20 or 30min) andmaintained
a plateau.
It is well known that crosstalk between the adrenergic, opioidergic,
nitrergic and serotoninergic pathways occurs at central and peripheral
levels. For example, opioid and adrenergic receptors are located at the
locus coeruleus and alpha-2 adrenergic receptors are localised on
capsaicin-sensitive afferent ﬁbres (Chen et al., 2007; Li and Eisenach,
2001; Fairbanks et al., 2002; Stein et al., 2009). This fact could explain
the observation that all the antagonists used were able to reverse the
antinociceptive effects of 5-Fisa and 5-Clisa in the tail ﬂick model. It
could be that the presence of ﬂuoro or chloro atoms in their structures
confers better solubility, facilitating their access to central sites of action.
Behavioural alterations such as motor uncoordination and sedation
might be misinterpreted as analgesia and produce false positive effects
(Tabarelli et al., 2004). In the present study, oral administration of
oxindoles did not causemotor impairment as evaluated by either forced
locomotion in the rotarod or spontaneous locomotion in the open-ﬁeld
test. Thus, the possibility that the antinociceptive effect of the com-
pounds tested is due to any degree of motor impairment or sedation is
very low. We also observed that DMSO per se had any toxic or anti-
inﬂammatory/antinociceptive effect. Colucci et al. (2008) had demon-
strated that the solvent has an antinociceptive effect when adminis-
tered by different routes. However in that paper authors used a
volume of 0.1 ml DMSO to each animal. In the present study we used
a volume of 0.3 μl DMSO per animal (corresponding to the higher
dose used, i.e., 10 mg/kg), a volume 333-fold lower than that used in
the paper, demonstrating that this volume has any effect.
We had previously showed that other analogue of Convolutamydine
A, with a bromide atom at position 5, had signiﬁcant effect in inﬂamma-
tory (Fernandes et al., 2014) or antinociceptive models (Figueiredo
et al., 2013). In those papers the effects were observed with doses rang-
ing from 0.01 to 30 mg/kg. To the formalin-induced licking behaviour
the molecule with a 5-Br substituent did not demonstrate any effect at
1st phase, and a signiﬁcant effect at 2nd phase of the model was ob-
served with 1 or 10 mg/kg doses. In the present work the new sub-
stances differ in the substituents. Either iodine, ﬂuoride, chloride or
methyl substituents at position 5 increase the activity of the molecule.
Fig. 7. Effects of 5-Iisa, 5-Fisa, 5-Clisa and 5-Meisa in the formalin-induced licking model. Mice were pretreated with atropine (muscarinic antagonist, 1 mg/kg, ip), naloxone (opioid an-
tagonist, 5mg/kg, ip), mecamylamine (nicotinic antagonist, 2mg/kg, ip), yohimbine (alpha-2 adrenergic antagonist, 2mg/kg, ip), L-nitro argininemethyl ester (L-NAME, inhibitor of nitric
oxide synthase, 3 mg/kg, ip) or ondansetron (5-HT3 serotoninergic antagonist, 0.5 mg/kg, ip), 15 min before oral administration of substances (10 mg/kg, po) or vehicle. The results are
presented as the mean ± SD (n = 6–10) of the time that mice spent licking the formalin-injected paw. Statistical signiﬁcance was calculated by ANOVA followed by Bonferroni's test.
*P b 0.05 when comparing treated mice to vehicle-treated mice and #P b 0.05 when comparing antagonist-treated groups with substances-treated animals.
18 T.B.S. Giorno et al. / Pharmacology, Biochemistry and Behavior 135 (2015) 13–19In this regard these substances demonstrate a signiﬁcant effect even in
the 1st phase of formalin-induced licking. All of them also demonstrate
an effect in the hot plate model at doses of 0.1 mg/kg. It may be that
these substituents confer stability to themolecule or facilitate the inter-
action between the molecule and the biological target increasing its
effects.
In conclusion, the data from the present study show that oxindoles
exert pronounced systemic antinociception in chemical (formalin, glu-
tamate and capsaicin-induced pain) and spinal (tail ﬂick) models of
nociception. In addition, the antinociceptive effects of the oxindoles
were antagonised by L-NAME, naloxone, and ondansetron, but not by
atropine in the formalin test (Table 1). Thus, these results suggest that
oxindoles are able to produce antinociception by the activation of the
nitric oxide, opioid or serotoninergic pathways.Table 1
A summary of the possible mechanism of action to 5-Iisa, 5-Fisa, 5-Clisa and 5-Meisa.
Receptor/System involved
Opioid NO Muscarinic Nicotinic α2-adrenergic 5HT3
Substance F TF F TF F TF F TF F TF F TF
5-Iisa Y Y Y – – – – – – – Y –
5-Fisa Y Y Y Y – Y Y Y – Y Y Y
5-Clisa Y Y Y Y – Y Y Y – Y Y Y
5-Meisa Y Y Y – – Y Y – – – Y Y
F, formalin-induced licking; TF, tail ﬂick; –, without effect.Acknowledgments
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